HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reckitt Sells Skin-Care Brand E45 To Karo In £200m Deal

Executive Summary

Karo Pharma is poised to expand its portfolio in the UK with the acquisition of leading skin-care brand E45 from Reckitt.

You may also be interested in...



Karo Strengthens Foot Care Offering As It Closes Lamisil Deal

Sweden's Karo has extended its footprint and geographical reach into new markets by closing its acquisition of topical antifungal brand Lamisil from Haleon.

New Owner Karo Invests Significantly In E45 In UK Including Relaunch And Line Extensions

Sweden's Karo Pharma is continuing to invest in its OTC portfolio, relaunching E45 in the UK supported by a seven figure marketing campaign and adding new lines to the popular skin-care brand. 

Adcock Kept Cash Back For Two Major Deals, Prioritizes Partnerships

Adcock Ingram intends to continue seeking partnership deals with multinational firms, after failing to complete two significant acquisitions during its financial year ended 30 June 2022.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel